BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26317995)

  • 1. Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.
    Chen HH; Horng MH; Yeh SY; Lin IC; Yeh CJ; Muo CH; Sung FC; Kao CH
    PLoS One; 2015; 10(8):e0135530. PubMed ID: 26317995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
    Bazelier MT; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; Vestergaard P; de Vries F
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):507-14. PubMed ID: 22392882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of fracture with thiazolidinediones: disease or drugs?
    Bazelier MT; Vestergaard P; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2012 Jun; 90(6):450-7. PubMed ID: 22488176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
    Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus.
    Filion KB; Joseph L; Boivin JF; Suissa S; Brophy JM
    Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):785-96. PubMed ID: 21671441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Filion KB; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):343-50. PubMed ID: 19998318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
    Yaturu S; Bryant B; Jain SK
    Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
    [No Abstract]   [Full Text] [Related]  

  • 16. Time-dependent risk of fracture in adults with type 2 diabetes receiving anti-diabetic drug: A one-stage network meta-analysis.
    Shen Y; Shi Q; Zou X; Meng W; Tian H; Du L; Li S
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3780. PubMed ID: 38367257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones and fractures in men and women.
    Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
    Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer and bone fractures in observational follow-up of the RECORD study.
    Jones NP; Curtis PS; Home PD
    Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone as a target of type 2 diabetes treatment.
    Lecka-Czernik B
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1085-90. PubMed ID: 19777397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
    Koro C; Barrett S; Qizilbash N
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.